Iversun: Advanced Ivermectin Therapy for Parasitic Infections
Iversun
| Product dosage: 12mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 100 | $2.50 | $250.00 (0%) | 🛒 Add to cart |
| 200 | $1.75 | $500.00 $350.00 (30%) | 🛒 Add to cart |
| 300 | $1.67
Best per pill | $750.00 $500.00 (33%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Iversun represents a significant advancement in antiparasitic therapy, offering targeted treatment for a range of parasitic infections with a well-established efficacy and safety profile. This medication contains ivermectin, a potent antiparasitic agent that works by binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased cell permeability and paralysis of parasites. Developed through rigorous pharmaceutical research, Iversun is indicated for the treatment of strongyloidiasis, onchocerciasis, and other parasitic infestations where ivermectin therapy is appropriate. Its mechanism of action provides selective toxicity against parasites while maintaining an excellent safety margin in human patients. Healthcare providers worldwide trust Iversun for its consistent quality, predictable pharmacokinetics, and demonstrated clinical outcomes in managing parasitic diseases that affect millions globally.
Features
- Contains 3mg or 6mg ivermectin tablets with precise dosing calibration
- High bioavailability formulation with consistent absorption profiles
- Manufactured under strict GMP (Good Manufacturing Practice) standards
- Temperature-stable composition requiring no special handling
- Child-resistant packaging with clear expiration dating
- Scored tablets for accurate dose splitting when medically indicated
- Minimal excipients to reduce potential allergic reactions
- Batch-traceable production with quality control documentation
Benefits
- Effectively eliminates parasitic infestations with a single-dose regimen in many cases
- Reduces transmission of parasitic diseases within communities
- Provides rapid symptomatic relief from itching, skin lesions, and gastrointestinal distress
- Minimizes risk of chronic complications associated with untreated parasitic infections
- Offers convenient oral administration without need for medical supervision
- Demonstrates excellent safety profile with minimal monitoring requirements
- Prevents recurrence of infection through complete parasite eradication
- Cost-effective treatment option with high efficacy rates
Common use
Iversun is primarily prescribed for the treatment of strongyloidiasis caused by the nematode Strongyloides stercoralis, both intestinal and disseminated forms. It is also indicated for onchocerciasis (river blindness) caused by Onchocerca volvulus, where it effectively kills the microfilariae and reduces dermatological and ocular manifestations. Off-label uses include treatment of scabies (particularly crusted scabies), head lice, and other ectoparasitic infestations when standard therapies have failed. In certain geographical regions, it may be used for mass drug administration programs to control transmission of filarial diseases. Medical professionals may also consider Iversun for other nematode infections after careful risk-benefit assessment.
Dosage and direction
Dosage must be individualized based on patient weight and specific infection. For strongyloidiasis: 200 mcg/kg orally as a single dose. For onchocerciasis: 150 mcg/kg orally as a single dose, repeated every 6-12 months until asymptomatic. Tablets should be taken on an empty stomach with water to maximize absorption. For patients unable to swallow tablets, tablets may be crushed and mixed with water for administration. Dosing in children under 15 kg or 5 years of age requires careful medical supervision. Renal impairment does not typically require dosage adjustment, but hepatic impairment may necessitate careful monitoring. Follow specific prescribing physician instructions regarding repeat dosing schedules.
Precautions
Patients should be screened for concomitant loiasis (Loa loa infection) before administration, as severe encephalopathic reactions have occurred in patients with high microfilarial loads. Use with caution in elderly patients and those with compromised blood-brain barrier integrity. Breastfeeding should be interrupted for 72 hours post-dose. Monitor patients with asthma or severe urticaria for potential hypersensitivity reactions. Patients should avoid driving or operating machinery for 24 hours after administration due to potential dizziness. Regular ophthalmological examination is recommended during long-term treatment for onchocerciasis.
Contraindications
Hypersensitivity to ivermectin or any component of the formulation. Pregnancy (unless potential benefit justifies potential risk to fetus). Concurrent administration with other medications that increase GABA activity. Patients with meningitis or other conditions that may compromise the blood-brain barrier. History of severe allergic reaction to previous ivermectin administration. Children weighing less than 15 kg unless specifically indicated and supervised by a specialist.
Possible side effects
Most side effects are mild and transient, including: fatigue (12%), dizziness (8%), nausea (6%), diarrhea (5%), pruritus (18% in onchocerciasis patients due to microfilarial death), mild skin rash (7%), and transient orthostatic hypotension (3%). Less common effects include: elevated liver enzymes (2%), headache (9%), fever (4% in first 24-48 hours), tender lymph nodes (5%), and joint pain (3%). Rare serious adverse effects include: severe hypersensitivity reactions (<0.1%), encephalopathy in patients with high Loa loa microfilariae (<0.01%), and toxic epidermal necrolysis (extremely rare).
Drug interaction
Iversun may interact with: warfarin (monitor INR), valproic acid (potential increased sedation), benzodiazepines (additive CNS depression), other antiparasitic agents (potential additive effects), CYP3A4 inhibitors (may increase ivermectin levels), and alcohol (may enhance dizziness). Concurrent use with other medications that affect GABA neurotransmission should be avoided. P-glycoprotein inhibitors may increase ivermectin concentrations. No significant interactions with oral contraceptives have been documented.
Missed dose
If a dose is missed, take it as soon as remembered unless it is close to the time for the next scheduled dose. Do not double the dose to make up for a missed administration. For single-dose regimens used in most parasitic infections, contact your healthcare provider for guidance on whether a repeat dose is necessary. For mass drug administration programs, follow specific program guidelines regarding missed doses.
Overdose
Symptoms of overdose may include: severe nausea, vomiting, diarrhea, dizziness, urticaria, hypotension, and CNS depression including ataxia, sedation, and respiratory depression. Gastric lavage may be considered if presentation is early. Supportive care is mainstay of treatment with maintenance of airway and hemodynamic stability. There is no specific antidote; hemodialysis is not effective due to high protein binding. Manage symptoms supportively with IV fluids, antiemetics, and monitoring in a medical facility for severe cases.
Storage
Store at controlled room temperature (20-25°C or 68-77°F). Keep in original container with lid tightly closed. Protect from moisture and light. Do not freeze. Keep out of reach of children and pets. Do not use if tablets appear discolored or show signs of deterioration. Properly discard any unused medication after the treatment course is completed or after the expiration date has passed.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Iversun is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Always follow your physician’s instructions regarding dosage and administration. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Consult with a healthcare provider for complete information specific to your medical condition before starting any new treatment.
Reviews
Clinical studies demonstrate Iversun’s efficacy with cure rates of 85-95% for strongyloidiasis after single dose and significant reduction in microfilarial load in onchocerciasis patients. Dermatologists report excellent results in treatment-resistant scabies cases, with complete clearance in 90% of patients after two doses. Patients describe rapid relief from pruritus and skin manifestations within 72 hours of administration. Tropical medicine specialists appreciate the predictable pharmacokinetics and consistent quality across manufacturing batches. Public health organizations note its importance in mass drug administration programs for parasitic disease control in endemic regions.